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Introduction:  The  rapid  and  complex  evolution  of  bacterial  resistance  mechanisms  in Klebsiella
pneumoniae  producing  extended-spectrum  -lactamases  and  carbapenemases  in Klebsiella  pneumoniae
is one  of the  most  signiﬁcant  threats  to public  health.  However,  questions  and  controversies  regarding
the  interactions  between  resistance  and virulence  in  multidrug-resistant  K.  pneumoniae  isolates  remain
unclear.
Methods:  A  retrospective  cohort  study  was  performed  with  100  K.  pneumoniae  isolates  recovered  from  a
tertiary care  university  hospital  centre  in  Lisbon  over a 31-year  period.  Resistance  and  virulence  deter-
minants  were  screened  using  molecular  methods  (PCR,  M13-PCR  and  MLST).
Results: The  predominant  virulence  proﬁle  (ﬁmH,  mrkDv1, khe)  was  shared  by  all  isolates,  indicative  of  an
important  role  of  type  1  and  3  ﬁmbrial  adhesins  and  haemolysin,  regardless  of  the  type  of  -lactamase
produced.  However,  accumulation  of virulence  factors  was  identiﬁed  in  KPC-3-producers,  with  a  higher
frequency  (p <  0.05)  of  capsular  serotype  K2  and  iucC  aerobactin  when  compared  with  non-KPC-3  -
lactamases  or carbapenemases.  Additionally,  9 different  virulence  proﬁles  were  found,  indicating  that
the KPC-3  carbapenemase  producers  seem  to adapt  successfully  to the  host  environment  and  maintain
virulence  via  several  pathways.
Conclusion:  This  study  describes  an  overlapping  of  multidrug-resistance  and  virulence  determinants  in
ST-14K2 KPC-3  K.  pneumoniae  clinical  isolates  that  may  impose  an  additional  challenge  in the  treatment
of  infections  caused  by  this  pathogen.
© 2018  Elsevier  Espan˜a,  S.L.U.  and  Sociedad  Espan˜ola  de  Enfermedades  Infecciosas  y  Microbiologı´a
Clı´nica.  All rights  reserved.
Determinantes  de  virulencia  y  resistencia  en  Klebsiella  pneumoniae  aisladas
en  un  centro  hospitalario  universitario  en  Portugal  durante  31  an˜os
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Introducción:  La  rápida  y compleja  evolución  de  los  mecanismos  de  resistencia  de  Klebsiella  pneumoniae
productora  de  beta-lactamasas  de  espectro  extendido  y carbapenemasas  en  Klebsiella  pneumoniae  es
una de  las  amenazas  más  importantes  para  la  salud  pública.  Sin  embargo,  aun  existe  controversia  sobre
la  interacción  entre  la resistencia  y la virulencia  en  aislados  de  K.  pneumoniae  resistentes  a múltiples
antimicrobianos.
∗ Corresponding author.
E-mail address: ccaneiras@gmail.com (C. Caneiras).
https://doi.org/10.1016/j.eimc.2018.11.001
213-005X/© 2018 Elsevier Espan˜a, S.L.U. and Sociedad Espan˜ola de Enfermedades Infecciosas y Microbiologı´a Clı´nica. All rights reserved.
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Infecciones bacterianas
Infección cruzada
Métodos:  Se  realizó  un  estudio  de  cohorte  retrospectivo  con  100  aislados  de  Klebsiella  pneumoniae  de
un  centro  hospitalario  universitario  en  Lisboa  durante  31  an˜os.  Los  determinantes  de la resistencia  y
virulencia  se  rastrearon  utilizando  métodos  moleculares  (PCR,  M13-PCR  y  MLST).
Resultados:  Todos  los  aislados  compartían  un  perﬁl  de  virulencia  predominante  (ﬁmH,  mrkDv1,  khe),  lo
que  indica  un papel  importante  de  las  adhesinas  ﬁmbriales  de  tipo 1 y 3,  y de  la  hemolisina,  indepen-
dientemente  del  tipo  de -lactamasa  producida.  Sin  embargo,  la acumulación  de  factores  de  virulencia
del serotipo  capsular  K2  y  la  aerobactina  iucC  se  identiﬁcó  con  una  mayor  frecuencia  en  las  cepas  produc-
toras  de KPC-3  (p <  0,05)  en  comparación  con  las  productoras  de  otras  -lactamasas  o carbapenemasas.
Además,  se encontraron  9  perﬁles  de virulencia  diferentes,  indicativos  de  que  las  cepas productoras  de
carbapenemasa  KPC-3  parecen  adaptarse  con  éxito  al entorno  y  mantener  la  virulencia  por  varias  vías.
Conclusión:  Este  estudio  describe  la  unión  de  resistencia  a múltiples  antimicrobianos  junto  con  determi-
nantes de  virulencia  en  aislados  clínicos  de  K.  pneumoniae  ST-14K2 KPC-3  lo que  puede  suponer  un desafío
adicional  en  el tratamiento  de  infecciones  causadas  por este  patógeno.
© 2018  Elsevier  Espan˜a,  S.L.U.  y  Sociedad  Espan˜ola  de  Enfermedades  Infecciosas  y  Microbiologı´a  Clı´nica.
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Klebsiella pneumoniae is a leading cause of healthcare-associated
nfections (HAIs), mainly responsible for urinary, respiratory and
loodstream infections and is now recognized as an urgent threat
o public health.1 Since the ﬁrst broad-spectrum -lactamase TEM-
, the rapid evolution of extended-spectrum -lactamases (ESBL)
nd carbapenemases, are one of the most signiﬁcant epidemiologic
hanges in infectious diseases.2 In Portugal, the ﬁrst carbapen-
mase was reported in 20093 and an important hospital-wide
issemination has been reported previously.4 However, the molec-
lar determinants of virulence and resistance were not described
o date.
Factors that are implicated in the virulence of K. pneumoniae iso-
ates can include the capsular serotype, iron-scavenging systems,
mbrial and non-ﬁmbrial adhesins,5 which have an important role
n the development of the infection.6 This knowledge can be fun-
amental to support efforts to control the threat to human health
osed by this bacterium with the purpose of recognize or under-
tand the emergence of clinically important clones within this
ighly genetically diverse species.7 Despite this, there remains a
ack of data regarding the virulence genes carried by K. pneumoniae
roducing beta-lactamases8 and, particularly little is known about
he virulence potential of KPC-producers.9
The aim of this study was evaluate the correlation of bacterial
esistance and virulence determinants among K. pneumoniae iso-
ates collected over a period of 31 years in a single tertiary-care
niversity hospital centre.
ethods
ospital centre setting and bacterial isolates
The K. pneumoniae isolates selected for this study were col-
ected between 1980 and 2011 from patients hospitalizaed at a
ertiary care university hospital centre located in Lisbon, with
pproximately 1100 beds that provides direct care to a pop-
lation of 370,000 people. All isolates were recovered from
npatients using standard operating procedures and identiﬁed
s -lactamase-producers by the laboratory, using conventional
ethods or automated systems like Vitek2
®
(BioMérieux, Marcy,
’Étoile, France) or MicroScan
®
(Snap-on, Kenosha, WI,  USA). The
solates were also sent to the Microbiology laboratory for additional
tudies. All isolates were maintained frozen in BHI broth plus 15%
lycerol at −80 ◦C. For analysis, the strains were grown in BHI Broth
or 18 h at 37 ◦C and seeded in nutrient agar or LB agar.Todos  los  derechos  reservados.
The K. pneumoniae strains were selected according to the iso-
lation period and the beta-lactamase type produced (determined
by preliminary antibiotic susceptibility proﬁle) and within this, by
random selection. The selected K. pneumoniae isolates were then
classiﬁed in 4 groups: group A (1980–1989, 15 strains susceptible
to -lactams, excluding aminopenicillins, indicative of broad-
spectrum -lactamases – BSBL production); group B (1990–2001,
12 strains with resistance to ceftazidime and reduced suscepti-
bility to cefotaxime, indicative of TEM-type extended spectrum
-lactamases – ESBL production), group C (2002–2008, 48 strains
with resistance to ceftazidime and cefotaxime, indicative of the
production of CTX-M-type extended spectrum -lactamases –
ESBL); group D (2009–2011), 27 strains with resistance to car-
bapenems, indicative of carbapenemase production.
Among the 100 isolates that were characterized in this study,
88 were clinical isolates: urine (n = 31); blood (n = 21), pus (n = 17),
sputum (n = 17), catheter (n = 1) and cerebrospinal ﬂuid (n = 1). The
remaining 12 isolates, included in group A, were from one colonized
healthcare professional (n = 1), colonized patients (n = 7) and hos-
pital environmental isolates like surfaces and medical equipment
(n = 4). The isolates were recovered in 26 wards or ICUs, mainly in
medical and cardiothoracic surgery wards.
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was  performed following
the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines by the standardized disk diffusion method
in Mueller-Hinton agar medium. Quality controls were carried
out in accordance with EUCAST (version 6.0, 2016), and Clinical
and Laboratory Standards Institute (CLSI) guidelines (M100-S20),
namely Escherichia coli ATCC 25922 and Escherichia coli ATCC 35218.
All isolates were tested with the same panel of antibiotics as fol-
lows: amoxicillin/clavulanic acid (20 g/10 g), cefoxitin (30 g),
cefotaxime (5 g), ceftazidime (10 g), imipenem (10 g), gentam-
icin (10 g), and ciproﬂoxacin (5 g). Isolates belonging to group
B, C and D were also tested for tigecycline (15 g) and fosfomycin
(200 g) in order to evaluate the role of these antibiotics as alter-
native therapeutic options.
The inhibition zones were interpreted according to EUCAST,
with the exception of fosfomycin, that was  interpreted following
the CLSI guidelines. The isolates were categorized as susceptible
(S), intermediate (I) and resistant (R) by applying the breakpoints
in the phenotypic test results. The imipenem minimum inhibitory
concentration (MICs) was  determined by the agar gradient test
(E-test
®
, Biomérieux, France) following the EUCAST guidelines.
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Table  1
Primers used in this study for the detection of beta-lactamases and virulence genes.
Gene DNA sequence (5′ to 3′) Amplicon size (bp) EMBL accession number (Genbank)
blaTEM F: GAAAGGGCCTCGTGATAC
R: TTACCAATGCTTAATCAGTGA
1058 HM749966
blaNDM  F: TATCGCCGTCTAGTTCTGCTG
R: ACTGCCCGTTGACGCCCAAT
871 AB604954
K2A  F: CAACCATGGTGGTCGATTAG
R: TGGTAGCCATATCCCTTTGG
531 EF221827
ﬁmH  F: TGTTCACCACCCTGCTGCTG
R: CACCACGTCGTTCTTGGCGT
512 NC 012731.1
mrkDV1 F: CGGTGATGCTGGACATGGT
R: CCTCTAGCGAATAGTTGGTG
300 EU682505.2
mrkDV2-4 F: CTTAATGGCGMTGGGCACCA
R: TCATATGCGACTCCACCTCG
950 AY225463.1AY225464.1AY225465.1
khe  F: TGATTGCATTCGCCACTGG
R: GGTCAACCCAACGATCCTGG
428 NC 012731.1
iucC  F: GTGCTGTCGATGAGCGATGC
R: GTGAGCCAGGTTTCAGCGTC
944 NC 005249.1
rmpA  F: ACTGGGCTACCTCTGCTTCA
R: CTTGCATGAGCCATCTTTCA
516 NC 012731.1
magA  F: TCTGTCATGGCTTAGACCGAT 1137 NC 012731.1
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tR: GCAATCGAAGTGAAGAGTGC
: forward primer; R: reverse primer.
esistance and virulence determinants
PCR based screening for the most commonly found -lactamase
amilies was performed with speciﬁc primers (blaSHV, blaDHA,
laCMY, blaCTX-M) including carbapenemase genes (blaKPC, blaIMP,
laVIM and blaOXA).10 The virulence factors were assessed by PCR
ith speciﬁc primers for K2 serotype (K2A), ﬁmbrial adhesins type
 (ﬁmH) and type 3 (mrkDv1 and mrKDV2-4), haemolysin (khe), aer-
bactin (iucC), mucoid (rmpA) and hypermucoviscosity phenotype
magA). The primers were designed in our study (Table 1).
Polymerase chain reactions were performed using the com-
ercial kit puReTaq Ready-To-Go PCR Beads (GE Healthcare
®
)
ccording to the manufacturer’s instructions. Subsequently the
CR products were resolved in agarose gel 1%, in TBE (1×),  and
tained with GelRed (Biotium). Positive and negative controls were
ncluded in all PCR assays. Resulting PCR products were submit-
ed to puriﬁcation using the JETquick Spin Column Technique PCR
uriﬁcation Kit (Genomed
®
), according to producer’s instructions
nd were sequenced at Macrogen Korea and STABVida Portu-
al. Searches for nucleotide sequences were performed with the
LAST program, available at the National Center for Biotechnology
nformation Web  site (http://www.ncbi.nim.nih.gov/). Multiple-
equence alignments were performed with the ClustalX program,
vailable at the European Bioinformatics Institute Web  site
http://www.ebi.ac.uk/Tools/msa/clustalw2).
olecular typing by M13-PCR ﬁngerprinting
Clonal relatedness was established by M13-PCR ﬁngerprinting,
ased on randomly ampliﬁed polymorphic DNA analysis.11 Strains
lassiﬁed as genetically related and assigned to the same lineage
ere identiﬁed with letters (A–Z). Different numbers were assigned
o more closely related strains (≤2 bands) and differentiate mem-
er’s types as subtypes (e.g., A1, A2).
ultilocus sequence typing (MLST)
MLST was performed as previously described12 on 25 selected
solates representing each of the -lactamases currently with
ore clinical relevance: CTX-M-15 (n = 8) and KPC-3 (n = 17).
he sequences were performed at Macrogen Korea and submit-
ed to the MLST database for allele attribution. The Klebsiellapneumoniae database is available at the Pasteur MLST site
(http://www.pasteur.fr/mlst/). Last accessed at May 2, 2018.
Statistical analysis
The statistical signiﬁcance of comparisons made through-
out this study was carried out by Fisher Exact Test, for
which we used the computer program available in http://www.
graphpad.com/quickcalcs/index. A p-value <0.05 was considered
statistically signiﬁcant.
Ethical approval
Isolates were obtained as part of routine diagnostic testing and
were analyzed anonymously. All data were collected in accordance
with the European Parliament and Council decision for the epi-
demiological surveillance and control of communicable disease
in the European Community. Epidemiological data were collected
from clinical records. The study proposal was also approved by
Research Ethics Committee of Faculty of Medicine, University of
Lisbon, Portugal.
Results
Antimicrobial susceptibility patterns
This study included the susceptibility proﬁle of K. pneumoniae
strains isolated from 1980 to 2011 against a uniform panel of antibi-
otics (Fig. 1). All isolates from group A except one (93.3%, 14/15)
were susceptible to all cephalosporins and 13 isolates showed resis-
tance to gentamicin (86.7%, 13/15). All the strains included in group
B (n = 12) were resistant to ceftazidime (100.0%, 12/12). Moreover,
66.7% (8/12) and 50.0% (6/12) showed resistance to gentamicin and
ciproﬂoxacin. Among the isolates of group C it was observed that
84.8% (39/46) and 82.6% (38/46) of the isolates were resistant to
ceftazidime and cefotaxime, respectively. Additionally, resistance
to gentamicin (82.6%, 38/46) and ciproﬂoxacin (76.1%, 35/42) was
also found.Among the 27 strains belonging to group D, 96.3% (26/27) were
resistant to cefotaxime and ceftazidime, 74.1% of isolates (20/27)
were resistant to imipenem while 81.5% (22/27) and 40.7% (11/27)
were resistant to gentamicin and ciproﬂoxacin, respectively.
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Fig. 1. Antimicrobial susceptibility pattern of the 100 representative Klebsiella pneumoniae strains isolated from patients with healthcare-associated infections. AMC:
amoxicillin/clavulanic acid; FOX: cefoxitin: CAZ: ceftazidime; CTX: cefotaxime; GM:  gentamicin; CIP: ciproﬂoxacin; IMP: imipenem.
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The isolates of groups B–D were also tested for tigecycline and
osfomycin in order evaluate the role of these antibiotics as an
lternative therapeutic option as well to understand the evolu-
ion of their resistance patterns over the study period (Fig. 2).
ig. 2 shows the phenotypic characterization of K. pneumoniae
solates. The isolates resistant to tigecycline found ranged from
.3% (1/12) among broad-spectrum -lactamase producers, to
9.6% (8/27) in carbapenemase producers. A high frequency of iso-
ates with clinically intermediate susceptibility to tigecycline was
ound (ranging from 48.1% to 83.3%) when compared with fos-
omycin (0%). The susceptibility to fosfomycin was 100% (broad and
xtended-spectrum -lactamases producers) and 88.9% (period
009–2011). Fosfomycin showed the highest activity to all -
actamase-producing isolates (88.9%) (Fig. 1), in comparison with
entamicin (3.7%) or ciproﬂoxacin (33.3%).dentiﬁcation of the ˇ-lactamases
Results of the identiﬁcation of -lactamases in K. pneumoniae
re shown in Table 2. The 15 K. pneumoniae isolates in group A against Klebsiella pneumoniae isolates.
(1980–1989) presented both TEM-1 and SHV-1 broad-spectrum
-lactamases. Among the 12 isolates in group B (1990–2001),
seven (58.3%, 7/12) presented the TEM-10 and ﬁve (41.7%, 5/12)
the TEM-24 extended-spectrum -lactamases (ESBL). All 46 iso-
lates (100.0%, 46/46) in group C (2002–2008) were positive for
cefotaxime-hydrolyzing CTX-M-15 ESBL. The 27 isolates in group
D (2009–2011) presented the KPC-3 carbapenemase alone (59.3%,
16/27) or in combination with other -lactamases, namely the
broad-spectrum -lactamase SHV-11 (14.8%, 4/27) and the ESBL
SHV-35 (3.7%, 1/27) and CTX-M-15 (22.2%, 6/27). The genes blaDHA,
blaCMY, blaIMP, blaVIM, blaNDM and blaOXA were not detected in our
collection.
Detection of virulence genes
Virulence genes as ﬁmH and mrkD adhesins, khe toxin, iucC
siderophore, K2 capsular type as well the magA and rmpA gene that
confers a hypermucoviscosity and mucoid phenotype, were inves-
tigated in all K. pneumoniae isolates. A prevalence of ﬁmH (96.0%),
mrkDv1 (90.0%), khe (63.0%) and K2 (23.0%) virulence genes was
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Table  2
Resistance determinants found in Klebsiella pneumoniae isolates (n = 100) recovered over a 31-year period in a tertiary care hospital centre in Lisbon, Portugal.
Group Resistance determinants
Total of isolates -Lactamases No. of isolates (%)
N  = 100
A BSBL n = 15 TEM-1, SHV-1 15 (100.0)
B  TEM-type ESBL n = 12 TEM-10 7 (58.3)
TEM-24 5 (41.7)
C  CTX-M-type ESBL n = 46 CTX-M-15 46 (100.0)
D  Carbapenemases n = 27 KPC-3 16 (59.3)
KPC-3, SHV-11 4 (14.8)
KPC-3, SHV-35 1 (3.7)
KPC-3, CTX-M-15 6 (22.2)
BSBL: broad-spectrum -lactamase; ESBL: extended-spectrum -lactamase.
Table 3
Distribution of virulence factors and their respective genes among Klebsiella pneumoniae isolates producing different types of -lactamases.
Virulence factor Target
gene
-Lactamases Number of isolates (%)
BSBL TEM-type ESBL CTX-M-type ESBL Carbapenemases
TotalTEM-1/SHV-1 TEM-10/TEM-24 CTX-M-15 KPC-3
n  = 15 n = 12 n = 46 n = 27 N = 100
Fimbrial adhesins Type 1 ﬁmH  12 (80.0) 12 (100.0) 46 (100.0) 26 (96.3) 96 (96.0)
Type  3 Variant 1 mrkDV1 10 (66.7) 9 (75.0) 45 (97.8) 26 (96.3) 90 (90.0)
Variant 2–4 mrkDV2–4 4 (26.7) 0.0 1 (2.2) 1 (3.7) 6 (6.0)
Toxin  Haemolysin Khe 12 (80.0) 11 (91.7) 24 (52.2) 16 (59.0) 63 (63.0)
Capsular type K2 serotype K2A 4 (26.7) 3 (25.0) 0.0 16 (59.0)* 23 (23.0)
Siderophore Aerobactin iucC 0.0 0.0 0.0 6 (22.0)* 0.0
Protectines or invasins Mucoviscosity phenotype magA 0.0 0.0 0.0 0.0 0.0
0.
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* p < 0.05 KPC-3 producers vs non-KPC-3 producers; BSBL: broad-spectrum -lac
dentiﬁed. Only 6.0% of the isolates showed the mrkDV2-4 and iucC
ene. No magA and rmpA genes were ampliﬁed. All isolates analyzed
n = 100) presented at least one of the virulence genes studied.
The distribution of virulence genes by the -lactamase type
roduced is shown in Table 3. The ﬁmbrial adhesins ﬁmH
80.0–100.0%), mrkDV1 (66.7–97.8%) and hemolysin gene khe
52.2–91.7%) were identiﬁed in all K. pneumoniae -lactamase
ypes, although the iucC gene was only identiﬁed in KPC-3 (22.0%).
he K2 gene was identiﬁed in TEM-1/SHV-1 (26.7%), TEM-10/TEM-
4 (25.0%) and KPC-3 producers (59.0%). The mrkDV2–4 gene was
ore frequent (p < 0.05) among the TEM-BSBL isolates (26.7%)ompared with TEM-ESBL (0.0%), CTX-M-15 (2.2%) and KPC-3
3.7%). The K2 and iucC virulence genes were signiﬁcantly related
ith KPC-3 clinical isolates compared with strains with other -
actamases (p = 0.0267 and p = 0.0002, respectively).
able 4
irulence proﬁles and number of virulence genes identiﬁed in isolates of Klebsiella pneum
Number of virulence
genes
Virulence
proﬁlea
BSBL 
TEM-1/SHV-1 
n  = 15 
5 VP1 ﬁmH, mrkDv2–4 , khe, iucC, K2 0.0 
VP2  ﬁmH, mrkDv1 , khe, iucC, K2 0.0 
4 VP3  ﬁmH, mrkDv1 , khe, iucC 0.0 
VP4  ﬁmH, mrkDv1 , khe, K2 2 (13.3) 
3 VP5  ﬁmH, khe, K2 1 (6.7) 
VP6  ﬁmH, mrkDv1 , iucC 0.0 
VP7  mrkDv1 , khe, iucC 0.0 
VP8  ﬁmH, mrkDv2–4 , khe 4 (26.7) 
VP9  ﬁmH, mrkDv1 , K2 1 (6.7) 
VP10  ﬁmH, mrkDv1 , khe 2 (13.3) 
2 VP11  ﬁmH, khe 0.0 
VP12  mrkDv1 , khe 3 (20.0) 
VP13  ﬁmH, mrkDv1 2 (13.3) 
P: virulence proﬁle; BSBL: broad-spectrum -lactamase; ESBL: extended-spectrum -la
a Virulence genes found simultaneously in the same isolate.0 0.0 0.0 0.0 0.0
e; ESBL: extended-spectrum -lactamase.
The characterization of the virulence proﬁle (VP) was performed
in order to evaluate the simultaneously accumulation of virulence
genes in the same isolate, and numbered according the decreasing
number of virulence genes found (Table 3). According to Table 4,
three virulence proﬁles were predominant, namely VP10 (35.0%),
VP13 (27.0%) and VP4 (11.0%). The prevalent proﬁles found in the
-lactamase-producing K. pneumoniae isolates were those that pre-
sented less accumulation of virulence genes per isolate, namely the
VP1–3 (2 genes), VP10 (3 genes) and, ﬁnally, VP4 (4 genes). The
VP10 (ﬁmH, mrkDv1, khe) was  found in 35 isolates (35.0%) and was
shared by all -lactamase producers, namely by TEM-1 and SHV-1
(13.3%), TEM-10 and TEM-24 (50.0%), CTX-M-15 (50.0%) and KPC-
3 (14.8%). The VP13 (ﬁmH, mrkDv1) was found among 27 (27.0%)
strains and was  mainly detected in CTX-M-15 producers. Instead,
the VP4 (ﬁmH, mrkDv1, khe, K2)  was speciﬁcally found in KPC-3
oniae producing different types of -lactamases and carbapenemases.
TEM-type ESBL CTX-M-type ESBL Carbapenemases
TotalTEM-10/TEM-24 CTX-M-15 KPC-3
n = 12 n = 46 n = 27 N = 100
0.0 0.0 1 (3.7) 1 (1.0)
0.0 0.0 1 (3.7) 1 (1.0)
0.0 0.0 2 (7.4) 2 (2.0)
2 (16.7) 0.0 7 (25.9) 11 (11.0)
0.0 0.0 0.0 1 (1.0)
0.0 0.0 1 (3.7) 1 (1.0)
0.0 0.0 1 (3.7) 1 (1.0)
0.0 1 (2.2) 0.0 5 (5.0)
1 (8.3) 0.0 7 (25.9) 9 (9.0)
6 (50.0) 23 (50.0) 4 (14.8) 35 (35.0)
3 (25.0) 0.0 0.0 3 (3.0)
0.0 0.0 0.0 3 (3.0)
0.0 22 (47.8) 3 (11.1) 27 (27.0)
ctamase.
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roducers. KPC-3 isolates showed 9 virulence proﬁles (all except
P5, -8, -11 and -12) whereas in CTX-M-15 producing-isolates only
 were detected (VP10, -13 and -8).
enotyping by M13-PCR ﬁngerprinting and MLST results
The clonal relatedness of the K. pneumoniae isolates was  estab-
ished by M13-PCR ﬁngerprinting to address if there was  a common
lone between the group of different -lactamase producing iso-
ates or within the same -lactamase group. A polyclonal situation
as found with 33 different genotypes. No similar genotypes
ere identiﬁed among the different -lactamases groups, indi-
ating genetic variability. Despite this, genetically related isolates
ere identiﬁed within the same -lactamase group as follows:
n group A – broad-spectrum -lactamases producing strains –,
ith seven colonized patients and four environmental isolates, all
rom neonatology department, shared the same genotype; in group
, CTX-M-15 -lactamase producers, presented 4 main genotypes
ith isolates from different wards and, ﬁnally, in group D, 66.7% of
he KPC-3 producers shared the same genotype (genotype A). The
ntensive care unit of hematologic diseases, the thoracic surgery
epartment and the surgery observation room were the mainly
ffected wards, all sharing the KPC-3 type A genotype.
MLST was performed on CTX-M-15 (n = 8) and KPC-3 (n = 17)-
roducing clinical isolates for international comparative purposes.
he ST15 accounted for 62.5% (5/8) of the CTX-M-15 isolates ana-
yzed by MLST. Additionally, 5 distinct allelic proﬁles were found:
T133 (n = 1); ST147 (n = 1), ST276 (n = 1) for CTX-M-15 produc-
ng isolates, whereas the KPC-3 carbapenemase-producing isolates
ere ST11 (n = 2) and ST14 (n = 15). The ﬁrst two  KPC-3 isolates,
dentiﬁed in 2009, showed the ST11 and the remaining KPC-3 iso-
ates (2009–2011) exhibited the same combination of alleles across
he seven sequenced loci, corresponding to the ST14 (88.2% of the
PC-3 isolates).
iscussion
Multidrug resistant and virulent populations were, for a long
ime, non-overlapping13 but the virulence of K. pneumoniae and
he interplay between resistance and virulence is still poorly
nderstood.14 Available reports do not include the KPC-3 isolates
r ST14 clones15 and mainly report the hypermucoviscosity pheno-
ype, associated with pyogenic liver abscess.16 To our knowledge,
his is the ﬁrst study that characterizes the evolution of viru-
ence features of K. pneumoniae -lactamase-producers, including
arbapenemase producers recovered from patients with hospital-
cquired infections.
A comparison of the population structure and virulence factors
etween groups of strains with ESBL and KPC resistance mecha-
isms versus broad-spectrum -lactamase producers (BSBL) was
erformed. The BSBL strains showed a susceptibility proﬁle to -
actams and quinolones (>90%), that decreased to <60% among
EM-type ESBL producers and to <20% among CTX-M-type ESBL
roducers. It is of concern that KPC-3 carbapenemase producers
ere resistant to -lactams, quinolones and aminoglycosides, lim-
ting the therapeutic options to treat infections caused by these
acteria. According to the European Centre for Disease Prevention
nd Control, the rate of resistance to carbapenems in Portugal has
ncreased six-fold (0.3–1.8%) over the period from 2011 to 2014,17
ighlighting that special attention should be paid to carbapenem
esistance trends.The rate of resistance to tigecycline among TEM- and CTX-
-type extended-spectrum -lactamase producers was 8.5%,
n line with previous reports that mentioned <10% resistance
ates in wide-scale surveillance studies18 but surprisingly amongbiol Clin. 2019;37(6):387–393
carbapenem-resistant strains this resistance rate reached 30%, fol-
lowing the tigecycline commercialization in Portugal (2009). Of
relevance, also 48% of the KPC-3 isolates presented intermediate
susceptibility to tigecycline, a phenotype associated with uncertain
clinical therapeutic effect.
Of note, 89% of KPC-3 isolates were susceptible to fosfomycin
and the resistance rates found in all groups of isolates ranged from
8 to 11%, supporting fosfomycin as a therapeutic option for difﬁcult-
to-treat K. pneumoniae infections. The potential use of fosfomycin
has been reported by other authors and its ability to penetrate
through bioﬁlm layers.19 However, the report of FosA3 (resistance
to fosfomycin) and KPC-2 on a single plasmid and its likely clonal
spread are worrying and should be monitored.20
Type 1 and type 3 ﬁmbrial adhesins are mainly involved in
adherence to several cell types and in bioﬁlm formation21 which
protects bacteria against antibiotics and host defenses19 and can
act as a starting point of infection from medical devices.22 The
high prevalence (>90%) of type 1 and type 3 ﬁmbrial adhesins
observed in our study, together with the antimicrobial multiresis-
tance observed, can explain the persistence of this multiresistant
isolates for long time in the hospital environment and the difﬁ-
culty of their eradication. Out of 100 strains studied, 92 showed the
ﬁmH and mrkD genes in the same isolate, demonstrating a relation
between these two genes. Additionally, the virulence proﬁle VP10
(ﬁmH, mrkDv1, khe) with the genes encoding type 1 and type 3 ﬁm-
brial adhesins and haemolysin, a pore-forming toxin that makes
some nutrients available such as the ferrous ion in hemoglobin
and often associated with pathogenic microorganisms,23 were pre-
dominant in the K. pneumoniae collection and were shared by all
-lactamase producers, conclusive of a common pathogenic origin.
The KPC-producing strains were previously described as highly
resistant and low virulent strains and no speciﬁc virulence factors
have been identiﬁed.24 Nevertheless, this conclusion is sustained
in the absence of aerobactin and capsular K2 and mainly included
KPC-2 isolates.24,25 In addition, Siu et al. reported that known viru-
lence factors such as K1, K2, and K5 capsular polysaccharides, rmpA
and the aerobactin gene were absent in KPC-producing isolates
and that these strains present low virulence in murine lethality
model.26
Our data contrast with previous studies considering a higher
detection rate (p < 0.05) of K2 capsular antigen (59%) and aer-
obactin (22%) in KPC-3 K. pneumoniae isolates than in the
KPC-negative groups. The K2 antigen confers resistance to phago-
cytosis and serum resistance,27 being frequently associated with
severe infections28 and aerobactin is one of the siderophores (extra-
cellular ferric chelating agents) secreted by bacterial cells and play
a critical role in bacterial virulence given that iron bioavailability in
the host is extremely low and it is essential for microbial growth.29
Moreover, De Cassia Andrade Melo et al. reported the presence of
type 1 and type 3 ﬁmbrial adhesins and yersiniabactin siderophore
in KPC-2-producing K. pneumoniae isolates from Brazil,2 a coun-
try maintaining a close relationship with Portugal. However, the
bacterial sequence types of the isolates were not analyzed.
In conclusion, the ST14 KPC-3 K. pneumoniae clone has revealed
a higher virulence proﬁle diversity and ability to accumulate vir-
ulence genes in the same isolate, when compared with strains
producing other -lactamases. A deeper understanding of the viru-
lence and resistance traits of high-risk clones is the ﬁrst step toward
the development of more effective approaches to minimize the
impact of hospital acquired infections by multiresistant bacteria.Funding
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